Clinical trials: COPD Exacerbations
COPD Exacerbation, CHF
Evaluation of the Multidimensional Dyspnea Profile (MDP)
Aim of this multicenter prospective cohort study is the evaluation of the multidimensional qualities of dyspnea in a number of diseases using the Multidimensional Dyspnea Profile (Banzett et al, ERJ 2015).
- Conditions
- COPD Exacerbation, CHF, OSA, COPD
- Trial name
- NCT04090671
- Testing
- Multidimensional Dyspnea Profile
- Where
- 4 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
COPD, COPD Exacerbation
Clinical Feasibility of a Non-invasive Wearable Acoustic Device for Measuring Air Trapping in COPD
This is a pilot observational study during which the investigators will conduct a longitudinal assessment of air trapping (with up to 2 visits) in 40 patients with COPD and variable degrees of air trapping and 20 healthy controls…
- Trial name
- NCT04450368
- Testing
- Sylvee
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Respira Labs, Inc
COPD, Chronic Obstructive Pulmonary Disease
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Sensorum Health (Sensorum) is conducting a pilot study to determine if Sensorum's proprietary passive sensor network can be used to identify signals of early health decompensation in subjects prior to a hospitalization for…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, COPD Exacerbation, CHF
- Trial name
- NCT05865184
- Testing
- Data collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sensorum Health Inc.
Acute Exacerbation of COPD
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD
This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require…
- Trial name
- VENT-AVOID (NCT03255057)
- Testing
- Hemolung Respiratory Assist System, Invasive mechanical ventilation
- Where
- 32 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alung Technologies
COPD Exacerbation
COPD Exacerbation Alert System With urinE anaLysis Using the HEADSTART Device
The Headstart Test system is an in vitro diagnostic test intended for self-testing for the detection of five biomarkers of infection in the urine of patients diagnosed with chronic obstructive pulmonary disease (COPD).
- Trial name
- COPE-WEL (NCT04296318)
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- Mologic Ltd
Acute Exacerbations of COPD
Development of AECOPD Identification Tool (DETECT Study)
This study is an observational, multi-center and cross sectional study,to develop an identification tool on purpose of differentiating COPD exacerbation from patients with respiratory symptoms in community hospitals of China.
- Trial name
- NCT03556475
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
COPD, COPD Exacerbation
Chronic Obstructive Pulmonary Disease (COPD) Monitoring
The present feasibility study aims at assessing whether the EMG of respiratory muscles can serve as an objective marker of dyspnea in COPD patients.
- Trial name
- COPD (NCT04671888)
- Testing
- exercises
- Volunteers
- 30 people
- Sponsor
- Medtronic BRC
Copd Exacerbation Acute
A Therapy for Improving Symptoms in Patients With Acute Exacerbations of COPD by Hydrogen-Oxygen Generator With Neburlizer.
The purpose for this study is to determine safety and effectiveness of the oxyhydrogen generator with nebulizer through a therapy for improving symptoms in patients with acute exacerbations of copd.
- Trial name
- NCT04000451
- Testing
- oxyhydrogen, Oxygen, Conventional treatment
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Asclepius Meditec Inc.
COPD Exacerbation, COPD
Telemonitoring System for Early Diagnosis of COPD Exacerbations.
A tailored management of COPD patients would obviously allow to reduce costs for hospitalizations and improve quality of life. This management could benefit of the Information and Comunication Technology support, which can offer…
- Trial name
- NCT03739957
- Testing
- BPCO Media Kit
- Where
- 3 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Laboratori di Informatica Applicata
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
COPD, Exacerbation
A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD
COPD is a major cause of ill health and death in Australia with 40,000 hospital admissions, and a national cost of $898,000,000 annually.
- Trial name
- NCT00446667
- Testing
- mannitol
- Where
- 2 sites in Australia
- Sponsor
- Syntara
COPD Exacerbation
Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients
This study is intended to evaluate treatment effectiveness with budesonide/formoterol (BFC) and tiotropium tromide in patients new to ICS/LABA combination and LAMA therapies.
- Trial name
- NCT01917643
- Volunteers
- 2,396 people
- Sponsor
- AstraZeneca
Acute Cardiovascular, Pneumonia
Evaluation of Lung Doppler Signals in Patients Presenting to EMD
Historically, ultrasound has been unable to provide interpretable data from the lung parenchyma, mainly because of the high total ultrasound energy attenuation and scattering by the air in the lungs.
- Conditions
- Acute Cardiovascular, Pneumonia, Pulmonary Embolism, CHF Exacerbation
- Trial name
- NCT01961141
- Where
- Israel
- Sponsor
- Echosense Ltd.